Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18387943
Rybin VO, et al. (2008) Phorbol 12-myristate 13-acetate-dependent protein kinase C delta-Tyr311 phosphorylation in cardiomyocyte caveolae. J Biol Chem 283, 17777-88 18387943
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y397-p - FAK (mouse)
Modsite: sVsEtDDyAEIIDEE SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y397‑p, FAK iso2 (mouse): Y428‑p, FAK iso4 (mouse): Y397‑p, FAK iso9 (mouse): , FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
PP1 H2O2 inhibit treatment-induced increase

Y420-p - Fyn (mouse)
Modsite: RLIEDNEytARQGAK SwissProt Entrez-Gene
Orthologous residues
Fyn (human): Y420‑p, Fyn iso2 (human): Y417‑p, Fyn iso3 (human): Y365‑p, Fyn (mouse): Y420‑p, Fyn (rat): Y420‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
phorbol_ester no change compared to control

Y397-p - LYN (mouse)
Modsite: RVIEDNEytAREGAK SwissProt Entrez-Gene
Orthologous residues
LYN (human): Y397‑p, LYN iso2 (human): Y376‑p, LYN (mouse): Y397‑p, LYN iso2 (mouse): Y376‑p, LYN (rat): Y397‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
phorbol_ester no change compared to control

Y311-p - PKCD (mouse)
Modsite: TTEsVGIyQGFEKKP SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Fyn (mouse)
KINASE Src (mouse)
KINASE LYN (mouse)
KINASE PDGFRB (mouse)
KINASE Yes (mouse)
KINASE Abl (mouse)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (mouse) transfection of wild-type enzyme, phospho-antibody, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
norepinephrine no change compared to control
endothelin no change compared to control
PDGF increase
H2O2 increase
GF109203X H2O2 no effect upon treatment-induced increase
PP1 H2O2 inhibit treatment-induced increase
AG1478 H2O2 no effect upon treatment-induced increase
imatinib H2O2 no effect upon treatment-induced increase
AG1295 H2O2 no effect upon treatment-induced increase
U73122 H2O2 no effect upon treatment-induced increase
phorbol_ester increase
GF109203X phorbol_ester no effect upon treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase
imatinib phorbol_ester no effect upon treatment-induced increase
AG1295 phorbol_ester no effect upon treatment-induced increase
H2O2 phorbol_ester no effect upon treatment-induced increase
EGF no change compared to control

Y332-p - PKCD (mouse)
Modsite: ILDNNGTyGKIWEGS SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y334‑p, PKCD iso2 (human): Y365‑p, PKCD (mouse): Y332‑p, PKCD iso2 (mouse): Y358‑p, PKCD (rat): Y332‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Fyn (mouse)
KINASE Src (mouse)
KINASE PDGFRB (mouse)
KINASE Yes (mouse)
KINASE LYN (mouse)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (mouse) transfection of wild-type enzyme, phospho-antibody, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
GF109203X H2O2 no effect upon treatment-induced increase
PP1 H2O2 inhibit treatment-induced increase
AG1478 H2O2 no effect upon treatment-induced increase
phorbol_ester increase
GF109203X phorbol_ester no effect upon treatment-induced increase
PP1 phorbol_ester inhibit treatment-induced increase

T505-p - PKCD (mouse)
Modsite: FGEGRAstFCGtPDY SwissProt Entrez-Gene
Orthologous residues
PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
norepinephrine increase
U73122 norepinephrine inhibit treatment-induced increase
endothelin increase
PDGF increase
H2O2 no change compared to control
phorbol_ester increase
U73122 phorbol_ester no effect upon treatment-induced increase

Y424-p - Src (mouse)
Modsite: RLIEDNEytARQGAK SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast), myocyte-heart, SYF (fibroblast)
Cellular systems studied:  cell lines, primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
phorbol_ester no change compared to control
H2O2 increase
PP1 H2O2 inhibit treatment-induced increase